Oral disorders, saliva secretion, and oral health-related quality of life in patients with primary Sj € ogren's syndrome Chemosensory function, burning sensations in the tongue (BST), halitosis, saliva secretion, and oral health-related quality of life (OHRQoL) were investigated in patients with primary Sj€ ogren's syndrome (pSS). In 31 patients with pSS and 33 controls, olfactory and gustatory functions were evaluated. Self-reported complaints of dysgeusia, BST, and halitosis were recorded. Saliva secretion rates were measured and OHRQoL was assessed using the short-form Oral Health Impact Profile (OHIP-14). Patients had significantly lower olfactory (8.8 AE 3.5 vs. 10.7 AE 1.2) and gustatory (18.9 AE 7.1 vs. 25.4 AE 4.3) scores than controls, and significantly more patients complained of dysgeusia (58.1% vs. 0%), BST (54.8% vs. 6.1%), and halitosis (41.9% vs. 0%). A significantly greater proportion of patients with pSS had ageusia (19% vs. 0%), hypogeusia (32% vs. 12%), anosmia (13% vs. 0%), or hyposmia (29% vs. 9%). Significantly lower saliva secretion rates (ml min À1 ) were observed in patients with pSS for stimulated (0.62 AE 0.40 vs. 1.57 AE 0.71) and unstimulated (0.08 AE 0.07 vs. 0.29 AE 0.17) saliva. The mean OHIP-14 score was significantly higher in patients with pSS (16.2 AE 10.8 vs. 2.7 AE 3.1) and was positively correlated with dysgeusia, BST, and halitosis. In conclusion, patients with pSS reported higher occurrence of dysgeusia, BST, and halitosis, and demonstrated relatively impaired chemosensory and salivary functions. The patients' poorer OHRQoL was associated with dysgeusia, BST, and halitosis.
Sj€ ogren's syndrome (SS) is an autoimmune disease that affects mainly women. The prevalence of SS has been shown to range between 0.05% and 1% in European populations (1, 2) . The disease can be divided into primary (pSS) and secondary (sSS) Sj€ ogren's syndrome (3) . The main manifestations of pSS are fatigue, and dryness of the mouth and eyes, along with muscle and joint pain (4) . For a pSS diagnosis, patients have to fulfill at least four out of the following six classification criteria: dry mouth; dry eyes; reduced tear secretion; reduced saliva secretion; histopathology of minor salivary glands showing infiltrates of lymphocytes; and the presence of autoantibodies to Ro/SSA and/or La/SSB (5) . The presence of any four of the six items indicates pSS, as long as either histopathology or serology is positive. Moreover, the presence of three of four of the objective criteria also justifies classifying patients as having pSS. On the other hand, the sSS diagnosis is used for patients with underlying autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, or scleroderma) diagnosed before developing their sicca symptoms (6) .
The lower saliva secretion observed in patients with pSS can have a major negative impact on their oral health and may contribute to mucosal infection and dental caries, in addition to difficulties in speaking, eating, and swallowing (7) . Oral complaints are shown to play an important role in the oral health-related quality of life (OHRQoL) in these patients (6, 8, 9) . Fatigue, pain, and systemic manifestations may also have an impact on general health-related quality of life (4, 10) .
Several studies on the oral aspects of pSS have focussed on factors related to lower salivary secretion (11) (12) (13) . A few studies have reported on taste and smell impairments in patients with pSS (14) (15) (16) , but little is known about chemosensory disorders and other oral complaints, such as dysgeusia, burning sensations in the tongue (BST), and halitosis. Chemosensory disorders include gustatory and olfactory dysfunctions, in which the senses of taste or smell can be reduced, distorted, or totally absent. Olfactory disorders are classified into anosmia (complete loss of smell), hyposmia (reduced ability to smell), and dysosmia (distorted smell perception) (17) . Classification of gustatory disorders follows a similar scheme, namely ageusia (complete loss of taste), hypogeusia (partial loss of taste), and dysgeusia (distorted taste perception in the presence of normal stimuli) (18) . Many patients with chemosensory disorders experience burning sensations or numbness in the mouth, especially in or on the tongue. These may originate in the gustatory nerve fibres (19) . Patients are diagnosed with burning mouth syndrome (BMS) if they experience intense BST, or burning in other mucosal membranes, lasting for at least 4-6 months, which may or may not be associated with normal clinical and laboratory findings (20) . Burning mouth syndrome may be classified into two clinical forms: primary, in which the organic local/systemic causes cannot be identified, and neuropathological pathways are involved; and secondary, caused by local, systemic, or psychological factors (21) . Halitosis (or oral malodour, defined as an unpleasant breath odour of oral or extra-oral origin), is another common oral complaint that can be associated with low salivary secretion (22) or chemosensory disorders (23) .
The aim of this study was to compare olfactory and gustatory function, salivary flow, BST, dysgeusia, halitosis, and OHRQoL in patients with pSS and age-and gender-matched controls.
Material and methods
The study was performed at the Dry Mouth Clinic at the Faculty of Dentistry, University of Oslo (UiO), Oslo, Norway. The protocol was approved by the Norwegian Regional Committee for Research Ethics (REK 2015/363). Thirty-one female patients with pSS and 33 female controls participated in the study; written informed consent was obtained from all participants. The patients with pSS had been referred from the Department of Rheumatology at the Oslo University Hospital, where they had been classified according to the American-European Consensus Group criteria (5) . The controls were recruited from UiO. Participants' medical history, chronic diseases, use of medications, social status, occupational status, and lifestyle habits (such as smoking) were recorded. Both controls and patients with pSS were required to be between 30 and 80 yr of age and were continuously recruited to the study. The exclusion criteria for the controls were as follows: subjective mouth and eye dryness; and presence of chronic diseases.
The participants were instructed not to eat, drink, or smoke for 1 h before their appointment at the Dry Mouth Clinic. They completed OHRQoL questionnaires, and a detailed patient medical history was recorded. A questionnaire was used to assess participants' experience of dysgeusia, BST, and halitosis (Table 1) . Open-ended questions were also asked for participants to describe their experience of dysgeusia, BST, and halitosis. Participants were examined by specialists in both oral surgery and oral medicine and also by general dentists. The sialometry, olfactory, and gustatory assessments were carried out as described below.
Using a standardized protocol, unstimulated whole saliva (UWS) and chewing-stimulated whole saliva (SWS) were collected from all participants to determine salivary secretory rates. Saliva collection was performed in preweighed plastic cups placed on ice, and UWS was collected first for 15 min. Participants then each chewed a paraffin wax tablet (Ivoclar Vivadent, Schaan, Lichtenstein) for approximately 30 s, swallowed any saliva in the mouth, and then continued chewing for another 5 min, expectorating the SWS regularly. Saliva samples were weighed and secretion rates were calculated for UWS and SWS (g ml À1 = ml min À1 ). Before olfactory testing, participants were asked to score their own general subjective smell perception on a visual analogue scale (VAS) from 0 to 10, where 0 = no smell perception and 10 = very good smell perception. An identification test, using 12 odour pens (Sniffin' Sticks-Screening; Burghart Messtechnik, Wedel, Germany) was used for the cognitive evaluation of olfactory function. The pens were positioned in front of the participant's nose, approximately 2 cm from both nostrils, for a maximum of 3-4 s. The participants were instructed to choose from four possible answers on a multiple-choice scoring card. The answers chosen by each participant were recorded on a protocol sheet, and the data were summarized for each participant. A normative classification (24) was used to define anosmic (score: 0-5), hyposmic (score: 6-9), and normosmic (score: 10-12) participants.
Before gustatory testing, participants were asked to score their subjective taste perception (on a VAS of 0-10, in which score 0 = no taste perception and score 10 = very good taste perception). A gustatory assessment was conducted after thoroughly explaining the testing procedure Table 1 Questionnaire for dysgeusia, burning sensations in the tongue (BST), and halitosis to the participants. Gustatory function was evaluated using taste strips (25, 26) with four basic taste qualitiessweet, sour, salty, and bitter -and each was tested at four different concentrations. Taste strips (length 8 cm, tip area 2 cm 2 ; Burghart Messtechnik) were gently rubbed on both sides of the anterior tip of the extended tongue, starting with the weakest concentration. The taste qualities were presented in a random manner. This protocol resulted in a total of 32 values for each participant. A chart with names of the four taste qualities was placed in front of the participants during testing so that the participants chose the taste quality with forced choice. The participants were allowed to rinse their mouths with water during the gustatory testing. A normative classification (25) was followed to distinguish between aguesic (score: 0-12), hypogeusic (score: 13-18), and normogeusic (score: 19-32) participants.
Information about OHRQoL was gathered using the 14-item short form of the Oral Health Impact Profile (OHIP-14) (27) (28) (29) . The total OHIP-14 sum score ranges from 0 to 56, giving an overall indication of the patient's OHRQoL. A high OHIP-14 score indicates a poor OHRQoL.
Statistical analyses
Statistical analyses were performed using SPSS version 24.0 (IBM, Armonk, NY, USA). An independent samples t-test was used for comparing normally distributed continuous variables in the patient and control groups. A chi-square test was used to compare dichotomous variables, and Pearson's correlations were used to measure the strength and direction of linear relationships between pairs of continuous variables. A multivariate linear regression analysis was used to adjust for characteristics such as age and smoking. All differences were considered significant at P < 0.05.
Results
Participant characteristics and demographic variables are presented in Table 2 . The participants in the control and pSS groups had a comparable mean age. The two groups did not differ significantly in their social status and smoking habits. Only seven of the patients with pSS used drugs related to pSS, and on average they used significantly more medications unrelated to pSS than did controls. Significantly lower mean AE SD saliva secretion rates were found in patients with pSS than in controls for both stimulated (0.62 AE 0.40 ml min À1 vs. 1.57 AE 0.71 ml min À1 ) and unstimulated (0.08 AE 0.07 ml min À1 vs. 0.29 AE 0.17 ml min À1 ) saliva. The measured mean olfactory and gustatory scores were lower in the patient group than in the control group (Table 3 ). The two groups were further divided into two subgroups based on participants' age: subgroup 1 (30-50 yr) and subgroup 2 (51-80 yr). Olfactory and gustatory testing showed that the participants in the pSS group had significantly lower mean olfactory and gustatory scores (Table 3 ) than the controls in both age groups. The differences in mean olfactory and gustatory scores between patients with pSS and controls were greater in subgroup 2 than in subgroup 1.
The pSS group had significantly lower mean selfreported smell scores (6.7 AE 3.0 vs. 8.3 AE 1.3, P = 0.01) and taste scores (6.6 AE 2.7 vs. 8.3 AE 1.3, P = 0.003) than the control group. In the pSS group, significant, positive correlations were found between the measured and self-reported olfactory scores (r = 0.69), and between the measured and self-reported gustatory scores (r = 0.41). The mean olfactory and gustatory scores were also positively correlated with each other in the pSS group (r = 0.51).
Gustatory testing categorized significantly more patients with pSS as ageusic and hypogeusic and significantly fewer with normal sense of taste than in the Values are given as mean AE SD. Statistically significant difference between patients and controls: ᵃP < 0.001; ᵇP < 0.0001.
control group (Table 4) . Similarly, olfactory testing showed that there were significantly more anosmic and hyposmic patients with pSS and fewer normosmic patients with pSS than controls (Table 4 ). In the pSS group, only weak correlations were found between saliva secretion rates and their olfactory (r SWS = 0.15/ r UWS = À0.03) and gustatory (r SWS = 0.04/ r UWS = À0.20) scores. Similarly, weak correlations were found between the olfactory/gustatory scores and the number of medications taken (r = À0.13/0.04) or disease duration (r = À0.14/0.02).
The frequency of complaints of dysgeusia, BST, and halitosis in the two groups are shown in Table 5 . While none of the controls complained of dysgeusia or halitosis, more than half of patients with pSS reported dysgeusia and about 40% complained of halitosis. Patients with pSS reported a significantly higher frequency of BST than did controls (54.8% vs. 6.1%). Cross-tabulations showed significant differences between patients with pSS and controls in self-reported complaints of dysgeusia (v 2 = 26.7, P < 0.0001), BST (v 2 = 18.2, P < 0.0001), and halitosis (v 2 = 17.4, P < 0.0001). Eighteen patients with pSS who complained of dysgeusia described the taste as metallic, sour, bitter, harsh, or rotten. These patients reported the dysgeusia as a persisting problem that disappeared temporarily during meals. Among 17 patients with pSS complaining of BST, 42% stated that this sensation accompanied food intake, especially sharp/spicy and sour food items. Thirteen patients with pSS complained of halitosis as a persisting daily problem, although they mentioned that they could manage their daily halitosis problem by the frequent use of chewing gums, zinc tablets and other saliva-stimulating tablets. In the pSS group, only weak correlations were found between saliva secretion rate and dysgeusia (r SWS = 0.10/r UWS = À0.06), BST (r SWS = À0.29/r UWS = À0.28) and halitosis (r SWS = 0.32/ r UWS = 0.06). Similarly, only weak correlations were found between dysgeusia/BST/halitosis and patients' age (r = À0.33/r = 0.09/r = 0.06, respectively), number of medications taken (r = À0.01/r = 0.02/r = À0.07, respectively), and disease duration (r = 0.09/r = 0.15/ r = 0.08, respectively).
The pSS group had a statistically significantly higher mean OHIP-14 sum score than the control group (16.2 AE 10.8 vs. 2.7 AE 3.1, P < 0.001). Scores in all domains of OHIP-14 (functional limitation, physical limitation, psychological limitation, and social limitation) were higher in patients with pSS than in controls. In the pSS group, the mean OHIP-14 sum score was moderately and positively correlated with dysgeusia (r = 0.40), BST (r = 0.39) and halitosis (r = 0.33). The mean OHIP-14 sum score was weakly negatively correlated to olfactory score (r = À0.16), gustatory score (r = À0.28), age (r = À0.15) and weakly positively correlated to saliva secretion rates (r SWS = 0.02/r UWS = 0.06).
Discussion
The principal findings of this study were that the patients with pSS: (i) had poorer olfactory and gustatory function; (ii) more often reported experiencing dysguesia, BST, and halitosis; (iii) had lower salivary secretion rates; and (iv) had poorer OHRQoL than the control group. However, within the groups, no significant correlations were found between saliva secretion rates and the presence of dysgeusia, BST, halitosis, or olfactory and gustatory scores. The OHRQoL was found to be associated with dysgeusia, BST, and halitosis. Moreover, weak associations were found between the OHRQoL and age/gustatory function/olfactory function or saliva secretion rates.
To our knowledge, this is the first study reporting on the presence and possible associations between chemosensory disturbances, BST, halitosis, salivary gland function, and OHRQoL in patients with SS. Dysgeusia, BST, and halitosis were found to be common complaints among patients with pSS. The findings are consistent with other studies in which the impairment of taste and smell function in patients with SS has been reported (14) (15) (16) . However, in the literature there are no comparable studies regarding the occurrence of dysgeusia, BST, and halitosis among patients with pSS. In the present study, gustatory dysfunction was found to be more pronounced than olfactory dysfunction, which is consistent with some studies (14, 15) and contradictory to one (16) . A possible reason behind the contradiction may be related to the difference in methods of Table 4 Categorization of patients with primary Sj€ ogren's syndrome and controls according to the gustatory and olfactory classification Table 5 Frequency of dysgeusia, burning sensations in the tongue (BST), and halitosis in patients with primary Sj€ ogren's syndrome and in controls testing smell function. An attempt was made to detect the cognitive smell function using smell identification test in the present study, whereas the chemosensory threshold (which reflects peripheral sensory impairment) was assessed by KAMEL and coworkers (16) . An ideal way of testing smell function would involve assessing threshold, detection, and identification tests, but because of time limitations only identification testing was performed in the present study. Some studies indicate that hyposalivation may cause smell and taste impairments (14, 16) , as well as a burning sensation in the mouth (30) . Meanwhile, contradictory results rejecting salivary factors as responsible for taste performance have also been reported (31) . In the present study, the patients with pSS had significantly lower salivary secretion rates than the controls. However, within the groups, weak correlations were found between salivary secretion rates and the presence of oral disorders, suggesting that low salivary flow was not directly responsible for the oral disorders examined in this study. An interesting finding in the present study was the relatively high percentage of ageusic and hypogeusic patients with pSS. While ageusia is a rare condition, reported to account for less than 1% of patients with chemosensory dysfunction (32-34), 19.3% of the patients with pSS in the present study were categorized as ageusic. On the other hand, anosmia is one of the most common complaints of patients needing treatment for chemosensory disorders (32) (33) (34) ; this was also reflected in the present study, in which 12.9% of the patients with pSS were categorized as anosmic. Previous studies indicate that about half of the patients with complaints of anosmia and hyposmia experience a shift in food preferences and report an increased consumption of sugar and seasonings (32, 34) . Similarly, in another study, patients with gustatory dysfunction stated that their inability to taste also affected their eating habits (35) . Both an increase in food intake, in order to compensate for the missing sensory experience, and a reduction in food intake, because of unpleasant sensation and lack of appetite, can be observed in patients with chemosensory disorders (34) . This could be expected to result in either an increase or a decrease in body weight.
The correlations between self-reported smell/taste function and tested olfactory/gustatory function showed strong associations, indicating that these chemosensory disorders are somatic in nature and consistent with the patients' own experiences. Considering that smell and taste functions are known to reduce with age (36, 37) , it was of interest to examine whether impaired olfactory and gustatory function was related to age or to the pSS disease itself. The present findings confirmed that olfactory and gustatory functions were negatively correlated with age, both in patients with pSS and controls, but the presence of pSS disease significantly impaired these chemosensory functions. In the present study, both younger and older patients with pSS had significantly lower gustatory and olfactory mean scores than the corresponding controls.
More than half of the patients with pSS complained of BST, which for many was found to be related to food intake. Burning sensation in the mouth is a common complaint among patients with SS and has been considered enigmatic because the intensity of discomfort cannot be easily correlated to clinical symptoms (20) . As a result, these patients are usually not investigated thoroughly for this by health personnel (20, 23) . A similar problem is anticipated for patients complaining of dysgeusia and halitosis (23) . Given that a large proportion of patients with pSS in the present study experienced oral disorders on a daily basis, our findings highlight how these oral problems deserve considerably more attention.
Burning mouth syndrome usually diminishes the patients' quality of life, and 'psychological dysfunction' is common in patients with this diagnosis (38) . Consistent with this, the present study showed that dysgeusia, BST, and halitosis were correlated with mean OHIP-14 score. In contrast, no significant correlation was found between olfactory and gustatory scores and the mean OHIP-14 score in the present study. It may be concluded from the current findings that the OHRQoL of patients with pSS was more influenced by dysgeusia, BST, and halitosis than by reduced smell and taste functions. However, other studies have shown that patients with olfactory dysfunction have symptoms of depression that worsen with increasing severity of smell loss (39) . The OHIP-14 questionnaire is designed to examine certain aspects of OHRQoL. Presumably, a questionnaire better designed to detect taste and smell dysfunction is needed to gain more specific insight into the patients' chemosensory experiences and OHRQoL. Accordingly, it would be valuable to design a questionnaire that is specifically aimed at evaluating chemosensory functions and oral health.
Oral malodour is a problem that has received increasing attention over the last decades. In the present study, almost half of the patients with pSS complained of halitosis, while none of the controls did so. The main oral aetiological factors of this disorder are understood, and effective treatment strategies have been established (40) . Interestingly, clinicians have reported that one-third of the patients seeking treatment for halitosis do not actually have oral malodour and they therefore cannot be categorized as 'genuine halitosis' patients (23) . The presence of chemosensory disorders, such as smell and taste dysfunction, in these patients may provide an alternative explanation for this phenomenon, rather than it being caused by the production of volatile sulphur compounds (VSC) (23) . Given that saliva plays a key role in removing the malodorous VSC from the oral cavity (41), the complaints of halitosis among patients with pSS may be partly explained by their markedly impaired saliva secretion. However, as levels of VSC were not measured in the present study, it is at best speculative whether complaints of halitosis in these patients may be a result of chemosensory disorders rather than of oral production of VSC.
Only weak associations were found between dysgeusia, BST, halitosis, or chemosensory dysfunction and age, the number of medications taken, or the disease duration. Thus, within the limitations of this study, with a relatively low number of patients with pSS, none of these factors were found to be strongly associated. Only weak associations were found between the mean olfactory and gustatory scores, when compared with number of medications taken, disease duration, and salivary secretion rate. These findings may suggest that the olfactory and gustatory dysfunctions in patients with pSS may be partly caused by other immunopathological aspects of pSS.
One explanation for the high frequency of chemosensory and other oral complaints in patients with pSS may be found in the systemic inflammatory activity associated with pSS; that is, overexpression of interferon-inducible genes (42) and increased responses to stimulation with interferon-a and interferon-c in Bcells and monocytes (43) . Toll-like receptor pathways and interferon pathways act in collaboration in mediating the inflammatory responses in taste tissue, and hence may interfere with normal taste transduction and taste-bud cell turnover (44) . More studies at the cellular level, investigating the inflammatory activity in patients with pSS and its effect on the peripheral taste and smell organs, are necessary to understand the occurrence of these oral disorders in patients with pSS.
In conclusion, this study showed that patients with pSS had impaired olfactory and gustatory function, and reported a higher occurrence of oral disorders, such as dysgeusia, BST, and halitosis. Furthermore, the lower saliva secretion rates in the patients with pSS could not account for the oral dysfunctions observed. Finally, the patients with pSS reported poorer OHRQoL and this was associated with complaints of dysgeusia, BST and halitosis.
